BACKGROUND: Chronic obstructive pulmonary disease (COPD) is underdiagnosed. One barrier to diagnosis is the limited availability of spirometry testing, but in adults at risk for COPD, a normal pre-bronchodilator (pre-BD) peak expiratory flow (PEF) may rule out clinically significant COPD. OBJECTIVE: To identify post-BD airway obstruction using data from 13 708 individuals aged >or=40 years from the PLATINO and BOLD studies. METHODS: We evaluated different cut-off points of pre-BD. The PEF was obtained from a diagnostic-quality spirometer (not a mechanical PEF meter). At least one of the following COPD risk factors was present in 77% of the subjects: chronic respiratory symptoms; exposure to tobacco smoke, biomass smoke or dust in the workplace; or a previous diagnosis of asthma, COPD, emphysema or chronic bronchitis. RESULTS: Although the positive predictive value was low as expected, a pre-BD PEF of >or=70% predicted effectively ruled out Stages III and IV COPD of the Global Initiative for Chronic Obstructive Lung Disease. Among those with at least one risk factor, only 12% would require confirmatory spirometry using this criterion. CONCLUSIONS: Adding PEF measurement to a screening questionnaire may rule out severe to very severe COPD without the need for pre- and post-BD spirometry testing. Confirmation is needed from a study using inexpensive PEF meters or pocket spirometers with a staged screening protocol.
BACKGROUND:Chronic obstructive pulmonary disease (COPD) is underdiagnosed. One barrier to diagnosis is the limited availability of spirometry testing, but in adults at risk for COPD, a normal pre-bronchodilator (pre-BD) peak expiratory flow (PEF) may rule out clinically significant COPD. OBJECTIVE: To identify post-BD airway obstruction using data from 13 708 individuals aged >or=40 years from the PLATINO and BOLD studies. METHODS: We evaluated different cut-off points of pre-BD. The PEF was obtained from a diagnostic-quality spirometer (not a mechanical PEF meter). At least one of the following COPD risk factors was present in 77% of the subjects: chronic respiratory symptoms; exposure to tobacco smoke, biomass smoke or dust in the workplace; or a previous diagnosis of asthma, COPD, emphysema or chronic bronchitis. RESULTS: Although the positive predictive value was low as expected, a pre-BD PEF of >or=70% predicted effectively ruled out Stages III and IV COPD of the Global Initiative for Chronic Obstructive Lung Disease. Among those with at least one risk factor, only 12% would require confirmatory spirometry using this criterion. CONCLUSIONS: Adding PEF measurement to a screening questionnaire may rule out severe to very severe COPD without the need for pre- and post-BD spirometry testing. Confirmation is needed from a study using inexpensive PEF meters or pocket spirometers with a staged screening protocol.
Authors: A Sonia Buist; William M Vollmer; Sean D Sullivan; Kevin B Weiss; Todd A Lee; Ana M B Menezes; Robert O Crapo; Robert L Jensen; Peter G J Burney Journal: COPD Date: 2005-06 Impact factor: 2.409
Authors: Giuseppe Liistro; Carl Vanwelde; Walter Vincken; Jan Vandevoorde; Geert Verleden; Johan Buffels Journal: Chest Date: 2006-09 Impact factor: 9.410
Authors: Rogelio Pérez-Padilla; Juan Carlos Vázquez-García; María Nelly Márquez; José Roberto B Jardim; Julio Pertuzé; Carmen Lisboa; Adriana Muiño; María Victorina López; Carlos Tálamo; María Montes de Oca; Gonzalo Valdivia; Ana Maria B Menezes Journal: Respir Care Date: 2006-10 Impact factor: 2.258
Authors: Carlos Tálamo; Maria Montes de Oca; Ron Halbert; Rogelio Perez-Padilla; José Roberto B Jardim; Adriana Muiño; Maria Victorina Lopez; Gonzalo Valdivia; Julio Pertuzé; Dolores Moreno; Ana Maria B Menezes Journal: Chest Date: 2007-01 Impact factor: 9.410
Authors: David B Price; David G Tinkelman; R J Halbert; Robert J Nordyke; Sharon Isonaka; Dmitry Nonikov; Elizabeth F Juniper; Daryl Freeman; Thomas Hausen; Mark L Levy; Anders Ostrem; Thys van der Molen; Constant P van Schayck Journal: Respiration Date: 2005-12-05 Impact factor: 3.580
Authors: Peter M A Calverley; Julie A Anderson; Bartolome Celli; Gary T Ferguson; Christine Jenkins; Paul W Jones; Julie C Yates; Jørgen Vestbo Journal: N Engl J Med Date: 2007-02-22 Impact factor: 91.245
Authors: Marc Miravitlles; Miriam Calle; Francisco Alvarez-Gutierrez; Elena Gobartt; Francisco López; Antonio Martín Journal: Qual Life Res Date: 2006-04 Impact factor: 4.147
Authors: Timothy J Wilt; Dennis Niewoehner; Robert L Kane; Roderick MacDonald; Anne M Joseph Journal: Nicotine Tob Res Date: 2007-01 Impact factor: 4.244
Authors: Fernando J Martinez; David Mannino; Nancy Kline Leidy; Karen G Malley; Elizabeth D Bacci; R Graham Barr; Russ P Bowler; MeiLan K Han; Julia F Houfek; Barry Make; Catherine A Meldrum; Stephen Rennard; Byron Thomashow; John Walsh; Barbara P Yawn Journal: Am J Respir Crit Care Med Date: 2017-03-15 Impact factor: 21.405
Authors: Anamika Jithoo; Paul L Enright; Peter Burney; A Sonia Buist; Eric D Bateman; Wan C Tan; Michael Studnicka; Filip Mejza; Suzanne Gillespie; William M Vollmer Journal: Eur Respir J Date: 2012-06-27 Impact factor: 16.671
Authors: Francisco Franco-Marina; Rosario Fernandez-Plata; Luis Torre-Bouscoulet; Cecilia García-Sancho; Elisa Sanchez-Gallen; David Martinez; Rogelio Perez-Padilla Journal: NPJ Prim Care Respir Med Date: 2014-05-20 Impact factor: 2.871
Authors: Andrew Kouri; Samir Gupta; Azadeh Yadollahi; Clodagh M Ryan; Andrea S Gershon; Teresa To; Susan M Tarlo; Roger S Goldstein; Kenneth R Chapman; Chung-Wai Chow Journal: Chest Date: 2020-07-08 Impact factor: 9.410